PRDX4 Potentially Serves as an Independent Marker for Early Recurrence of Oral Squamous Cell Carcinoma
Anticancer Research · 2026
DOI: 10.21873/anticanres.18139 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, 2026. Verfasst von Taijiro Hashimoto und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Head and Neck Surgery, School of Medicine, Kanazawa Medical University, Uchinada, Japan. Hauptthemen laut MEDLINE: Peroxiredoxins, Mouth Neoplasms, Carcinoma, Squamous Cell, Neoplasm Recurrence, Local.
Abstract (Originalsprache)
BACKGROUND/AIM: Oral squamous cell carcinoma (OSCC), a main histological subtype of oral cavity cancer, remains one of the most prevailing tumors worldwide with the increasing incidence and mortality. Since a high rate of early local recurrence is one of the major risk factors for poor outcome of OSCC, its prognostic biomarkers are urgently needed. Peroxiredoxin 4 (PRDX4), a member of PRDXs, which are involved in the antioxidant defense, is a unique secreted subtype of PRDXs. A certain number of previous studies have disclosed that the overexpression of the PRDX4 protein has a clear relationship with tumor initiation and progression in many cancers. Furthermore, recent studies have revealed that PRDX4 promotes tumor development through the Wnt/β-catenin signaling pathway. MATERIALS AND METHODS: To assess the status of the PRDX4/β-catenin expression and its association with clinical outcomes, including early local recurrence in OSCC, we immunohistochemically examined PRDX4 expression levels and cytoplasmic β-catenin protein accumulation levels in a total of 72 postoperative OSCC samples. RESULTS: The immunohistochemically high expression of PRDX4 was significantly correlated with poorer early phase 2-year recurrence-free survival (RFS), associated closely with higher PRDX4 expression levels especially the OSCC nests of invasive fronts or perineural invasion. In addition, a multivariate Cox regression analysis revealed that PRDX4 was an independent prognostic factor for 2-year RFS. Moreover, high β-catenin accumulation is significantly associated with distant metastasis. A comparison of the combination of a high expression of PRDX4 and high β-catenin protein accumulation groups with the other groups only showed a significant predominance among men. CONCLUSION: The increased expression of PRDX4 may be a useful independent prognostic biomarker for recurrence of OSCC, especially in the early postoperative phase.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Head and Neck Surgery, School of Medicine, Kanazawa Medical University, Uchinada, Japan.
- Department of Pathology, Kanazawa Medical University Hospital, Uchinada, Japan.
- Department of Pathology, Kanazawa Medical University Hospital, Uchinada, Japan; oym@kanazawa-med.ac.jp.
- Department of Pathology and Laboratory Medicine, School of Medicine, Kanazawa Medical University, Uchinada, Japan.
- Department of Medical Science, School of Nursing, Kanazawa Medical University, Uchinada, Japan.
- Department of Molecular and Cellular Pathology, Graduate School of Medical Science, Kanazawa University, Uchinada, Japan.
Zitieren
APA
Hashimoto, T., Oyama, T., Zhang, Y., Ito, Y., Han, J., Liu, Y., Yoshida, M., Shioya, A., Okuro, M., Kitamura, M., & Yamada, S. (2026). PRDX4 Potentially Serves as an Independent Marker for Early Recurrence of Oral Squamous Cell Carcinoma. Anticancer Research. https://doi.org/10.21873/anticanres.18139
Vancouver
Hashimoto T, Oyama T, Zhang Y, Ito Y, Han J, Liu Y, et al. PRDX4 Potentially Serves as an Independent Marker for Early Recurrence of Oral Squamous Cell Carcinoma. Anticancer Research. 2026. doi:10.21873/anticanres.18139
BibTeX
@article{Hashimoto2026,
author = {Hashimoto, Taijiro and Oyama, Takeru and Zhang, Yangxian and Ito, Yukinobu and Han, Jia and Liu, Yao and Yoshida, Mitsuaki and Shioya, Akihiro and Okuro, Masashi and Kitamura, Morimasa and Yamada, Sohsuke},
title = {PRDX4 Potentially Serves as an Independent Marker for Early Recurrence of Oral Squamous Cell Carcinoma},
journal = {Anticancer Research},
year = {2026},
doi = {10.21873/anticanres.18139}
}
EUVIMED